Abstract Preparation

Call for Abstracts

We invite you to submit your abstract for the 2019 San Antonio Breast Cancer Symposium. 

To submit an abstract
 


Preparation

  • Abstract must be submitted online. To submit an abstract, please click here.
  • The abstract must be in English.
  • There is no limit to the number of abstracts submitted.
  • There is no limit to the number of authors listed on an abstract.
  • The size limit for the abstract (including title, body and tables) is 3400 characters. This does not include spaces.
  • Please see the submissions website for specific details regarding the inclusion of tables. Tables count for 320 characters.
  • Figures cannot be included in an abstract.
  • Any author who cannot present on a particular day of the week must provide that information by emailing c4asupport@ctimeetingtech.com.
  • Submitting an abstract online does not register you to attend the Symposium.  You can register for the Symposium at www.sabcs.org/Registration.

Submission Fee

  • Include a payment of $50.00 for each abstract submitted.  
  • A credit card payment is required.
  • The abstract fee is not refundable.
  • Abstracts are due by July 8 at 11:59 pm Central Time US.  

Submission

  • Please click here to submit an abstract for the 2019 San Antonio Breast Cancer Symposium. You are required to submit your abstract online.
  • When finished with your online submission, be sure to submit payment. Click the "Submit" button.  Abstracts received without a properly completed Disclosure Declaration will not be considered.  The size limit for the abstract (including title, body, and tables) is 3400 characters - this does not include spaces. Please see the submissions website for specific details regarding tables.
  • Any author who cannot present on a particular day of the week must provide that information upon submission. No rescheduling will be possible after July 8, 2019.
  • Abstracts are due by July 8 at 11:59 pm Central Time US. 
  • For questions about abstract submission, contact CTI Meeting Technology by phone 217-398-1792 or by email  sabcs@support.ctimeetingtech.com

Abstract Subject Categories

The subject categories for abstract submission are listed below. You must select the most appropriate category for your abstract and insert its corresponding number in the box on the abstract form. Please be aware that the Symposium Abstract Review Committee may re-categorize your abstract if doing so is deemed appropriate.

Subject Categories List

DETECTION/DIAGNOSIS

Axillary Nodes
101. Axillary Staging and Sentinel Nodes
Pathology
102. Diagnostic Pathology
103. Biopsy Techniques
104. Circulating Biomarkers and ctDNA
105. Circulating Tumor Cells
106. Micrometastases

Imaging and Screening
107. Breast Imaging - Mammography
108. Breast Imaging - MRI
109. Breast Imaging - Other Methods 
110. Molecular, Functional, and Novel Imaging 
111. Radiology - Tumor Monitoring
112. Screening

Other
113. Detection/Diagnosis - Other


TUMOR CELL AND MOLECULAR BIOLOGY

201. Angiogenesis
202. Animal Models
203. Ex vivo Models  
204. Apoptosis and Senescence
205. Cell Cycle Regulation
206. Cellular Mechanisms
207. DNA Damage and Repair
208. Drug Resistance
209. Endocrine Therapy and Resistance
210. Epigenetics
211. Epithelial-Mesenchymal Transition
212. Etiology/Carcinogenesis
213. Gene Therapy
214. Genetics - Germline Changes
215. Genetics - Somatic Changes
216. Genomics
217. Growth Factors
218. Hormonal Factors and Receptors
219. Immunology and Preclinical Immunotherapy
220. Mammary Development and Differentiation
221. Metabolism and Breast Cancer
222. Microenvironment - Stromal - Epithelial Interactions
223. MicroRNAs and Other Non-coding RNAs
224. Molecular Profiles
225. New Drugs and Mechanisms
226. Novel/Emerging Therapeutic Targets
227. Oncogenes/Tumor Suppressor Genes
228. Signaling Pathways
229. Stem/Progenitor Cells
230. Systems Biology of Breast Cancer
231. Telomeres/Telomerase
232. Tumor Heterogeneity/Molecular Subclassification
233. Tumor Progression, Invasion, and Metastasis
234. Virology
235. Tumor Cell and Molecular Biology - Other


PROGNOSTIC AND PREDICTIVE FACTORS

Prognostic Factors
301. Prognostic Factors - Clinical Testing and Validation
302. Prognostic Factor Index Scores

Biomarkers Predicting Treatment Sensitivity and Resistance
303. Predictive Biomarkers for Endocrine Therapies
304. Predictive Biomarkers for Chemotherapies
305. Predictive Biomarkers for Targeted Therapies
306. Predictive Biomarkers - General

Prognostic and Predictive Factors - General
307. Prognostic and Predictive Factors - Preclinical Studies
308.  Prognostic and Predictive Factors - Other


EPIDEMIOLOGY, RISK, AND PREVENTION
401. Epidemiology - Population Studies
402. Epidemiology - Genetic and Molecular 
403. Ethnic/Racial Aspects 
404. Familial Breast Cancer - Genetic Testing
405. Familial Breast Cancer - Molecular Genetics
406. Prevention - Behavioral Interventions
407. Prevention - Nutritional Studies
408. Prevention - Clinical Trials
409. Prevention - Preclinical Studies and Model Systems
410. Risk Factors and Modeling
411. Epidemiology, Risk, and Prevention - Other

 

PSYCHOSOCIAL, QUALITY OF LIFE, AND EDUCATIONAL ASPECTS

Social and Education Issues
501. Advocacy
502. Cost-Effectiveness
503. Disparities and Barriers to Care
504. Doctor-Patient Communication
505. Education

Quality of Life Issues
506. Palliation and Pain Management
507. Psychosocial Aspects
508. Quality of Life - Supportive Care
509. Survivorship Research

Other
510. Psychosocial, QOL, and Educational Aspects - Other


TREATMENT

Adjuvant Therapy
601. Adjuvant Chemotherapy
602. Adjuvant Endocrine Therapy
603. Adjuvant Therapy - Targeted
604. Adjuvant Therapy - Other

Advanced Disease Treatment
605. Advanced Chemotherapy
606. Advanced Endocrine Therapy
607. Advanced Therapy - Targeted
608. Advanced Therapy - Other

Surgery and Radiotherapy
609. Breast Conservation
610. Radiotherapy
611. Surgery
612. Reconstruction

Therapeutic Strategies
613. Neoadjuvant Chemotherapy
614. Neoadjuvant Endocrine Therapy
616. Antiangiogenic Therapy (Adjuvant and Metastatic)
617. Antibody-Based Regimens
619. HER2-Targeted Therapy
620. Immunotherapy (Clinical)
621. New Drugs and Treatment Strategies
622. Novel Targets and Targeted Agents
623. Signal Transduction Inhibitors
624. Toxicities - Management

Types and Sites of Breast Cancer
625. Bone Metastases
626. Brain Metastases
627. DCIS/LCIS
628. Male Breast Cancer
629. Inflammatory Breast Cancer

Research Resources
630. Patient Resources
631. Tissue and Data Banks
632. Clinical Trials Design and Management

Other
633. Treatment - Other


ONGOING CLINICAL TRIALS
701. Ongoing Clinical Trials (see rules below)

This category is for work that is ongoing. It is to inform and inspire, and/or to invite the collaboration of others. It is to not to discuss the trial results, either preliminary or formally completed - presentations with this type of information should be submitted as regular abstracts. 

Trials with any type of focus may be submitted (treatment, prevention, biomarker endpoints, supportive care, educational, and psychosocial endpoints). 

What should be presented in the abstract and eventually in the poster is: 

  • A brief background discussion
  • Trial design
  • Eligibility criteria
  • Specific aims
  • Statistical methods
  • Present accrual and target accrual
  • Contact information for people with a specific interest in the trial

Again, inclusion of preliminary or final trial results will disqualify an abstract in this category and is not allowed on the poster, though information on accrual to date or confirmation of feasibility is acceptable. 

Poster presentations in the Ongoing Clinical Trials category are not subject to SABCS pre-publication and embargo policies.